Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

Exclusion Criteria

• •Known congenital deficiency of C1s, C1r, C1q, C2, or C4
• •History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
• •Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
• •History of malignancy within 5 years prior to the screening visit
• •Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
• •Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
• •Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1